<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/united-therapeutics-co-logo-1200x675.png/query-dj0yMDIyMTEwNzE1MjcxNw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/united-therapeutics-co-logo-1200x675.png/query-dj0yMDIyMTEwNzE1MjcxNw"/>United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00. Following the transaction, the chief financial officer owned 18,876 shares of the company's stock, valued at $10,843,695.72. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website.</p><ul><li>The Top 3 Stock Picks at the World’s Greatest Hedge Fund</li></ul><p>James Edgemond also recently made the following trade(s): </p><ul><li>On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $573.03, for a total value of $5,730,300.00. </li><li>On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.58, for a total value of $5,785,800.00. </li><li>On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $576.93, for a total value of $5,769,300.00. </li><li>On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.61, for a total value of $5,726,100.00. </li><li>On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $568.83, for a total value of $5,688,300.00. </li><li>On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The stock was sold at an average price of $575.85, for a total value of $209,609.40. </li><li>On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The stock was sold at an average price of $572.21, for a total value of $5,513,815.56. </li><li>On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.86, for a total value of $5,778,600.00. </li><li>On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.18, for a total value of $5,771,800.00. </li><li>On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.88, for a total value of $5,748,800.00. </li></ul><h2>United Therapeutics Stock Performance</h2><hr/><hr/><p>Shares of UTHR stock opened at $568.58 on Friday. The stock's fifty day moving average is $558.07 and its 200-day moving average is $507.08. The stock has a market capitalization of $24.14 billion, a PE ratio of 20.99, a PEG ratio of 1.82 and a beta of 0.60. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. </p><ul><li>Liquidia: Court victory the awakening of an industry giant?</li></ul><p>United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics's revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.63 EPS.  As a group, analysts forecast that  United Therapeutics Corporation will post 27.64 earnings per share for the current fiscal year. </p><h2>More United Therapeutics News</h2><p>Here are the key news stories impacting United Therapeutics this week:</p><ul>   <li><span>Neutral Sentiment: </span>CEO Martine Rothblatt sold 9,500 shares for about $5.5 million, trimming her stake by 19%; CFO James Edgemond also sold 10,000 shares for about $5.7 million, reducing his ownership by 34.6%. These sizable insider transactions can make investors cautious about near-term sentiment. <i></i><span>Article Title</span></li>   <li><span>Neutral Sentiment: </span>Director Nilda Mesa also sold 258 shares, a smaller transaction that adds to the recent insider selling trend. <i></i><span>Article Title</span></li>   <li><span>Positive Sentiment: </span>HC Wainwright maintained a <strong>Buy</strong> rating and a <strong>$660</strong> price target, despite trimming its FY2030 earnings estimate slightly. Broader analyst coverage remains constructive, with a consensus rating of <strong>Moderate Buy</strong> and a target around <strong>$619.42</strong>, which may help support the stock. <i></i><span>Article Title</span></li> </ul><h2>Hedge Funds Weigh In On United Therapeutics</h2><ul><li>Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential</li></ul><p>Hedge funds have recently added to or reduced their stakes in the company. Torren Management LLC bought a new position in  United Therapeutics in the fourth quarter valued at about $26,000.  Activest Wealth Management boosted its holdings in  United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 56 shares during the last quarter.  Entrust Financial LLC bought a new position in  United Therapeutics in the fourth quarter valued at about $31,000.  International Assets Investment Management LLC boosted its holdings in  United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company's stock worth $45,000 after buying an additional 64 shares during the last quarter.  Finally, Wilmington Savings Fund Society FSB boosted its holdings in  United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after buying an additional 49 shares during the last quarter. Institutional investors own  94.08% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>UTHR has been the topic of several research analyst reports. Jefferies Financial Group  restated a &#34;buy&#34; rating on shares of United Therapeutics in a report on Monday, March 2nd. Royal Bank Of Canada decreased their price target on United Therapeutics from $707.00 to $701.00 and set an &#34;outperform&#34; rating on the stock in a report on Thursday, May 7th. Morgan Stanley  set a $516.00 price target on United Therapeutics in a report on Thursday, May 7th. Wells Fargo &amp; Company upgraded United Therapeutics from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and raised their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They issued an &#34;outperform&#34; rating and a $700.00 price target on the stock. Eleven analysts have rated the stock with a Buy rating and two have issued  a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $619.42.</p><p><b>Check Out Our Latest Stock Analysis on United Therapeutics</b></p><h2>United Therapeutics Company Profile</h2><p> (Get Free Report)</p><p>United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than United Therapeutics</li><li>MarketBeat Week in Review – 05/11 - 05/15</li><li>Viking Sails to All-Time Highs—Fundamentals Signal More to Come</li><li>Datavalut Gains Traction: 5 Reasons to Sell Now</li><li>TMC Stock: Why This Pre-Revenue Miner Is Worth Watching</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at United Therapeutics?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for United Therapeutics and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260413094022_pushgold-bullion-163553640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260413094022_pushgold-bullion-163553640.jpg"/></p><div><p>Trump's gold order: the announcement they won't put on the front page</p><p>On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...</p><p><span>Reagan Gold Group</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTA5MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTA5MQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260429162234_pushelon-musk-7465608640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260429162234_pushelon-musk-7465608640.jpg"/></p><div><p>Elon's new &#34;super startup&#34;</p><p>Adam O'Dell - the analyst who recommended Palantir before it became the top S&amp;P 500 performer - has identified...</p><p><span>Banyan Hill Publishing</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTE2MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTE2MQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260420143007_pushwallstreet.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="201" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260420143007_pushwallstreet.jpg"/></p><div><p>Your book is inside</p><p>The &#34;Sucker's Bet&#34; Most New Options Traders Fall For  Most people who try options lose money the same way. ...</p><p><span>Profits Run</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTAwNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTAwNQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260513164125_pushstock-exchange-4785086640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260513164125_pushstock-exchange-4785086640.jpg"/></p><div><p>Secret behind near perfectly timed stock trades…?</p><p>After 20 years of professional trading, Ross Givens says this is the single most lucrative market strategy he ...</p><p><span>Traders Agency</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTQ4Mw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTQ4Mw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260311160021_pushainewer-1.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260311160021_pushainewer-1.jpg"/></p><div><p>CODE RED: AI Meltdown Imminent?</p><p>After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...</p><p><span>Paradigm Press</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTE4OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTE4OA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260220101326_pushjb4-before.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260220101326_pushjb4-before.png"/></p><div><p>SpaceX eyes a 1.75 trillion valuation - here's what to know</p><p>Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...</p><p><span>Brownstone Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk0OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk0OA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260511203658_pushgoldnew-1.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260511203658_pushgoldnew-1.jpg"/></p><div><p>Oil is settling in yuan now - here's what that means for gold</p><p>Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...</p><p><span>Golden Portfolio</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTQxMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTQxMw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://mde-images.marketbeat.com/doc-conversion/2026/04/034166e16ffc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1600" height="899" original-src="https://imageproxy.pbkrs.com/https://mde-images.marketbeat.com/doc-conversion/2026/04/034166e16ffc.png"/></p><div><p>The cat is out the bag</p><p>Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...</p><p><span>Porter &amp; Company</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTMzMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTMzMA"/></p></div></div></div>                     </div>                 </div></div>

UTHR

<p>CFO James Edgemond of United Therapeutics (NASDAQ:UTHR) sold 10,000 shares at an average price of $574.47, totaling $5,744,700. This sale decreased his ownership by 34.63%, leaving him with 18,876 shares valued at approximately $10.84 million. Edgemond has made several similar transactions recently, contributing to a cautious sentiment among investors due to significant insider selling.</p>

United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares